79557-58-7

Upstream product

• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 106-95-6 allyl bromide 

Downstream Products

• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 79557-60-1 2,4-dihydroxy-3-propylbenzoic acid methyl ester 
• 79557-59-8 2,4-dihydroxy-3-(2-propenyl)benzoic acid methyl ester 
• 129249-88-3 methyl ester 2-hydroxy-4-hydroxyethoxy benzoic acid 
• 130334-06-4 2-hydroxy-4-[6-(6,7-dimethoxy-2-naphthalenyl)hexyloxy]-3-propylbenzoic acid 
• 118683-24-2 4-(4-Carboxy-2-methoxy-benzyloxy)-2-hydroxy-3-propyl-benzoic acid 
• 106627-31-0 diphenylmethyl 6-(4'-carbomethoxy-3'-hydroxy-2'-propylphenoxy)hexanoate 
• 106627-18-3 4-(5-Carboxy-pentyloxy)-2-hydroxy-3-propyl-benzoic acid methyl ester 

Relevant academic research and scientific papers

Substituted aryloximes

The present invention relates to substituted aryl oximes and methods of using them.

Indole derivative having piperidine ring

The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.

LEUKOTRIENE B4 ANTAGONISTS

This invention relates to compounds of Formula I and the stereoisomers and pharmaceutically acceptable salts thereof STR1 wherein R is alkyl, alkenyl, alkynyl, or cycloalkylalkyl;R 1 is alkyl; R 2 is hydrogen, alkyl;R 6 is alkyl;

Leukotriene B4 antagonists

This invention relates to compounds of Formula I and the stereoisomers and pharmaceutically acceptable salts thereof STR1 wherein R is alkyl, alkenyl, alkynyl, or cycloalkylalkyl; R1 is alkyl; R2 is hydrogen or alkyl; R6 i

Catechol carboxylic acids

The invention relates to catechol carboxylic acid derivatives of the formula STR1 wherein, R1 is STR2 acetyl, hydrogen, hydroxy or alkanoyloxy, R2 is STR3 hydroxy, hydrogen or alkanoyloxy, wherein R is hydrogen, lower alkyl or --(CH2)n --N--(lower alkyl)2, R3 is hydrogen, lower alkyl or amino, R4 is hydrogen, lower alkyl, halogen or amino A is STR4 wherein, R5 is hydrogen or acyl, R6 is hydrogen, halogen, lower alkyl, aryl or cycloalkyl, and R7 and R8, independently, are hydrogen, lower alkyl or halogen, or A is STR5 wherein, R5 is hydrogen or acyl, R9 is hydrogen, lower alkyl, R10 is hydrogen, lower alkyl or halogen, R11 is hydrogen, lower alkyl, cycloalkyl or halogen, m is 0 or 1, n is an integer of 2-10, provided, that no more than one of R1 or R2 can be hydroxy, alkanoyloxy or STR6 and when R is hydrogen, salts thereof with pharmaceutically acceptable bases or when R is --(CH2)n --N--(lower alkyl)2, salts thereof with pharmaceutically acceptable acids. The compounds of formula I are useful as agents for the treatment of inflammatory diseases such as arthritis, inflammatory bowel disease such as colitis, cardiovascular diseases such as myocardial ischemia, skin diseases such as psoriasis by topical administration, and bronchopulmonary diseases such as asthma.

Dihydroxynaphthalene derivatives

There are described dihydroxy naphthalene derivatives of the formula STR1 in which R1 is hydrogen, lower alkyl or benzyl, R2 is hydrogen, hydroxy or lower alkanoyloxy, R3 is hydrogen or lower alkyl, R4 is hydrog

Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes

Considerations of the possible similarities between leukotriene D4 and its prototypical antagonist, FPL 55712, led to the development of a new series of leukotriene antagonists incorporating a hydroxyacetophenone group (e.g., the toluic acids 1

Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives

A series of derivatives of 2,4-dihydroxy-3-propylacetophenone were prepared and examined for their ability to block leukotriene D4 (LTD4) induced contraction of guinea pig ileum. Straight-chain carboxylic acids where the carboxyl gro